CA-NEXTIVITY
15.3.2022 07:02:04 CET | Business Wire | Press release
Nextivity today announced that Nordic distributor Tura Scandinavia AB has the first European installation of Cel-Fi QUATRA 4000e underway. The new multi-carrier hybrid active DAS (distributed antenna system) for the EMEA market has been deployed at Elgiganten and Rusta stores in northern Stockholm, Sweden so customers and employees can now use their cell phones anywhere inside the stores, and experience good quality reception.
Spotty cellular coverage, poor voice quality, dropped calls, and dead zones continue to impact employees and customers in many retail buildings. Cel-Fi QUATRA 4000e is an affordable, all-digital, multi-carrier active DAS hybrid solution that solves this issue by providing uniform, high quality cellular signal throughout any commercial building. This industry-leading system is also carrier approved and guaranteed network safe.
“There was no cellular reception at all inside the Elgiganten and Rusta stores due to the metal construction of the buildings, which is common for commercial property in Sweden,” says Terje Skatterod, Senior Technology Officer at Tura Scandinavia, a Nordic distributor that offers mobile, data, and cellular equipment for retailers through a network of system integrators. “Cel-Fi QUATRA has improved the signal inside the stores by 25 dBM, which is equivalent to increasing the coverage by almost 100 times.”
“As Cel-Fi QUATRA is 5G-ready, building owners get a greater return on their investment with this modern solution which is upgradable,” explains Sverre Platou, Nextivity Brand Manager at Tura Scandinavia. “The system is also all-digital, using ethernet rather than coax cabling, which makes installation easier and reduces the installation cost to about a quarter of traditional repeater systems.”
“Cel-Fi QUATRA is starting to get a lot of attention in the Nordic region. Unlike other equipment, you don't need the RF skills to install it. You can simply use a local electrician to run the cabling and hook it up to the internet, and one telecom RF engineer to deploy the whole solution remotely,” Skatterod says.
Tura Scandinavia, which was named best European distributor in 2021 by Nextivity, has several installations of the new Cel-Fi QUATRA 4000e scheduled for other retailers in Sweden and throughout Europe. For more information about QUATRA, visit cel-fi.com/buy .
“Tura Scandinavia is a strong strategic partner for Nextivity, bringing our best-in-class cellular coverage solutions to the reseller community,” says David Cabanes, Nextivity Vice-President of European Sales. “With product offerings now available for enterprise, small and mid-size businesses, mobile, and micro solutions, we look forward to continuing to work with Tura Scandinavia to help their partners expand their capabilities and market reach.”
About Tura Scandinavia AB
Tura Scandinavia AB is a leading Nordic distributor of accessories in Audio, Video, Mobile, Data, Photography, TV, Gaming and SDA. Our philosophy is: a wide range, strong brands and fast delivery. The business was founded in Gothenburg in 1976 and we currently operate in Sweden, Denmark, Finland and Norway. The head office is located in Kungsbacka and the logistics center in Nässjö, Sweden.
About Nextivity
Headquartered in San Diego, Nextivity Inc. develops the award-winning, Cel-Fi family of products that deliver best-in-class connectivity for enterprise, business, residential spaces, and mobile cellular and public safety communication needs. Cel-Fi is the go-to solution for healthcare, government, hotels, retail, education, remote sites, parking garages, manufacturing, warehouses, as well as trucking and marine fleets. Cel-Fi products are available in 100 countries through mobile operators and a growing worldwide network of master distributors, systems integrators, installers, and resellers. Additional information is available at cel-fi.com , on Twitter , LinkedIn , and on Facebook .
Nextivity, the Nextivity logo, Cel-Fi, Smart Signal Booster, and Supercell are registered trademarks of Nextivity Incorporated in the United States and/or other countries. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005864/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom